OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.
Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- Angelini Pharma signed an exclusive global option agreement with Sovargen for SVG105, a potentially first-in-class antisense oligonucleotide targeting mTOR pathways for brain health disorders. - The deal includes an upfront payment and potential milestone payments up to approximately $550 million, plus tiered royalties on post-approval net sales. - SVG105 represents a novel therapeutic approach for drug-resistant epilepsy, addressing a significant unmet medical need where approximately 40% of patients remain uncontrolled despite treatment. - This partnership further strengthens Angelini Pharma's brain health portfolio, following recent strategic collaborations with GRIN Therapeutics, OmniAb, Cureverse, and JCR Pharmaceuticals.
- Tharimmune secured approximately $5.47 million in equity financing during Q2/Q3 2025 to advance its lead asset TH104, a buccal film formulation of nalmefene designed to protect military personnel and first responders from weaponized fentanyl exposure. - The FDA confirmed that no additional clinical trials are required for TH104's 505(b)(2) NDA submission for temporary prophylaxis against high-potency opioid contamination, utilizing an expedited "in silico" pathway. - TH023, the company's oral monoclonal antibody targeting TNF-alpha, demonstrated successful oral delivery of infliximab in preclinical studies using the proprietary Soteria® platform, with plans for first-in-human trials within 12 months. - The company strengthened its leadership team with key appointments including James Gordon Liddy, a former Navy SEAL commander, as Board Director and Strategic Advisor for national security initiatives.
- Tharimmune completed a $1.74 million registered direct public offering to fund working capital and general corporate purposes. - The clinical-stage biotechnology company is developing TH104 via a 505(b)2 pathway for opioid-induced respiratory depression in military personnel. - The company's expanded pipeline includes TH104 for chronic pruritus in primary biliary cholangitis and TH023 for autoimmune diseases. - Tharimmune's proprietary EpiClick Technology platform targets multiple solid tumors through multispecific biologics.
- Tharimmune announced key leadership changes with Sireesh Appajosyula becoming CEO and Vincent LoPriore appointed Executive Chairman in June 2025. - The company added James Gordon Liddy, a retired Navy SEAL Commander with national security expertise, to its board of directors to support TH104 development. - TH104 is a buccal film formulation designed to deliver opioid antagonist therapy for military personnel and first responders exposed to weaponized fentanyl and high-potency opioids. - The leadership appointments strengthen Tharimmune's strategic position as it advances its lead candidate through the 505(b)2 regulatory pathway for respiratory and nervous system depression prevention.
- Tharimmune received positive FDA feedback allowing a 505(b)(2) NDA submission for TH104 as prophylaxis against ultrapotent opioid exposure, with no additional clinical trials required. - The buccal film formulation of nalmefene (TH104) leverages existing safety and efficacy data, enabling an "in silico" submission using pharmacokinetic modeling to predict drug performance. - Beyond its original development for chronic pruritus in primary biliary cholangitis, TH104 now targets protection for military personnel and first responders entering areas contaminated with high-potency opioids.
